The use of epoetin beta in cardiac arrest victims: the impact on survival and neurological outcome

• Conditions: The aim of our prospective, randomized, multicentered and controlled research is to determine the impact of erythropoietin on survival and neurological outcome of cardiac arrest victims. On the basis of previous research we expect that giving erythropoietin early in the course of cardiopulmonary resuscitation would decrease the ischaemic and reperfusion damage to the brain and heart after a period of cardiac arrest and thus it would improve neurological outcome of these patients.; MedDRA version: 9.1Level: LLTClassification code 10007517Term: Cardiac arrest transient

• Registration Number: EUCTR2006-006453-27-SI
• Lead Sponsor: Zdravstveni dom dr. Adolfa Drolca Maribor

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2007-01-23
• Last Update Posted: 15 July 2013

Recruitment & Eligibility

• Status: Authorised-recruitment may be ongoing or finished
• Sex: All
• Target Recruitment: 200

Inclusion Criteria

The study includes cardiac arrest patients of 18 years old and more and with cardiac arrest of any aethyiology.
Are the trial subjects under 18? no
Number of subjects for this age range:
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range
F.1.3 Elderly (>=65 years) yes
F.1.3.1 Number of subjects for this age range

Exclusion Criteria

Excluding criteria are terminal malignant diseases and conditions incompatible with life.

Study & Design

• Study Type: Interventional clinical trial of medicinal product
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Main Objective: The aim of our prospective, randomized, multicenter and controlled research is to determine the impact of erythropoietin on survival and neurological outcome of cardiac arrest victims. On the basis of previous research we expect that giving erythropoietin early in the course of cardiopulmonary resuscitation would decrease the ischaemic and reperfusion damage to the brain and heart after a period of cardiac arrest and thus it would improve neurological outcome of these patients.;Secondary Objective: Secondary objectives of the study are the impact of erythropoietin on return of spontaneous circulation in cardiac arrest victims, survival to hospital admission, discharge from hospital, and 6-month survival after succesfull cardiopulmonary resuscitation of the cardiac arrest victims;Primary end point(s): To determine the impact of erythropoietin on survival and neurological outcome of cardiac arrest victims.